

# CITATION REPORT

List of articles citing

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

DOI: 10.1016/s1470-2045(13)70609-0  
Lancet Oncology, The, 2014, 15, 333-42.

**Source:** <https://exaly.com/paper-pdf/58951866/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
234	Multiple myeloma: optimal management and long-term disease control. <b>2014</b> , 121		
233	Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. <i>Blood Cancer Journal</i> , <b>2014</b> , 4, e243	7	13
232	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. <b>2014</b> , 64, 422-44		61
231	Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. <b>2014</b> , 2014, 652395		11
230	Lenalidomide and second malignancies in myeloma patients. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 253-4	21.7	10
229	Are we nearing an era of chemotherapy-free management of indolent lymphoma?. <b>2014</b> , 20, 5226-39		14
228	Maintenance therapy for multiple myeloma. <b>2014</b> , 28, 839-59		14
227	Update on second primary malignancies in multiple myeloma: a focused review. <b>2014</b> , 28, 1423-6		21
226	Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. <b>2014</b> , 371, 906-17		565
225	Current knowledge and future research directions in treatment-related second primary malignancies. <b>2014</b> , 12, 5-17		39
224	The evolving field of post-transplant therapy in multiple myeloma. <b>2014</b> , 4, 825-838		
223	Lenalidomide in Nonmalignant Disorders: A New Ray of Hope for Refractory Sarcoidosis. <b>2015</b> , 148, e188-e189		3
222	Maintenance therapy for multiple myeloma in the era of novel agents. <b>2015</b> , 2015, 279-85		9
221	Multiple Myeloma. <b>2015</b> , 145-156		0
220	Pathogenesis beyond the cancer clone(s) in multiple myeloma. <b>2015</b> , 125, 3049-58		181
219	The novel mechanism of lenalidomide activity. <b>2015</b> , 126, 2366-9		100
218	Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. <b>2015</b> , 100, 1340-9		33

217	Response. <b>2015</b> , 148, e189		
216	Consolidation and maintenance in de novo first-line multiple myeloma with modern agents. <b>2015</b> , 4, 9-22		1
215	Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients. <b>2015</b> , 8, 1277-84		
214	Expanding role of lenalidomide in hematologic malignancies. <b>2015</b> , 7, 105-19		25
213	Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma. <b>2015</b> , 7, 5949		
212	. <b>2015</b> ,		2
211	Cereblon binding molecules in multiple myeloma. <b>2015</b> , 29, 329-34		36
210	The risk of secondary primary malignancies after therapy for multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 3012-21	1.9	11
209	Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. <b>2015</b> , 11, 1643-58		
208	Autologous stem cell transplantation in multiple myeloma is not dead but alive and well. <b>2015</b> , 15, 149-54		9
207	Role of hematopoietic stem cell transplantation in multiple myeloma. <b>2015</b> , 15, 86-91		10
206	New cancers after autotransplantations for multiple myeloma. <b>2015</b> , 21, 738-45		28
205	Multiple myeloma: is a shift toward continuous therapy needed to move forward?. <b>2015</b> , 8, 253-6		7
204	Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. <b>2015</b> , 15, 110-4		27
203	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <b>2015</b> , 45, 94-105		10
202	To maintain or not to maintain: treatment forever in myeloma?. <b>2015</b> , 8, 26-29		0
201	Thalidomide improves clinical remission in children with Crohn's disease. <b>2015</b> , 100, 111		1
200	An update on the use of lenalidomide for the treatment of multiple myeloma. <b>2015</b> , 16, 1865-77		8

199	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1723-6	1.9	14
198	Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?. <b>2015</b> , 50, 1024-9		23
197	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. <b>2015</b> , 45, 335-43		4
196	The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents. <b>2015</b> , 75, 367-75		3
195	Blood and Marrow Transplant Handbook. <b>2015</b> ,		5
194	Current therapeutic strategies for multiple myeloma. <b>2015</b> , 20, 423-30		20
193	Reply to 'allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome'. <b>2015</b> , 50, 1483-5		
192	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. <b>2015</b> , 15, 592-8		2
191	Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 46-54	4.5	15
190	The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. <i>European Journal of Haematology</i> , <b>2015</b> , 94, 109-14	3.8	9
189	Bone cancer incidence by morphological subtype: a global assessment. <b>2015</b> , 26, 1127-39		75
188	Clinical treatment of newly diagnosed multiple myeloma. <b>2015</b> , 8, 595-611		7
187	Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. <b>2015</b> , 37, 61-7		14
186	Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. <b>2016</b> , 2016, 6848902		14
185	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. <b>2016</b> , 128, 2297-2306		37
184	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e506	7	49
183	Sequencing of nontransplant treatments in multiple myeloma patients with active disease. <b>2016</b> , 2016, 495-503		6
182	Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011. <b>2016</b> , 12, 5043-5051		8

181	Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. <b>2016</b> , 27, 1226-34	5
180	Lenalidomide - the new melphalan?. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1749-50	1.9
179	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <b>2016</b> , 127, 1102-8	72
178	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. <b>2016</b> , 127, 1109-16	79
177	Maintenance lenalidomide after transplantation: How much is enough?. <b>2016</b> , 122, 3762-3764	
176	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. <b>2016</b> , 122, 3831-3837	20
175	Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis. <b>2016</b> , 139, 2343-52	1
174	Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. <b>2016</b> , 5, 1694-701	5
173	Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study. <b>2016</b> , 107, 653-8	10
172	Is Maintenance Therapy for Everyone?. <b>2016</b> , 16 Suppl, S139-44	4
171	Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study. <b>2016</b> , 87, 1161-6	22
170	Management of multiple myeloma in resource-constrained settings. <i>Seminars in Oncology</i> , <b>2016</b> , 43, 690-694	3
169	Principles of Chemotherapy. <b>2016</b> , 171-185.e2	
168	Controversies in multiple myeloma: Evidence-based update. <i>Seminars in Oncology</i> , <b>2016</b> , 43, 666-675	5.5 6
167	Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. <b>2016</b> , 6, 22084	12
166	Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. <b>2016</b> , 101, e145-8	16
165	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApSE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. <b>2016</b> , 16, 290	5
164	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <b>2016</b> , 16, 387-94	11

163	Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. <b>2016</b> , 16, 46		1
162	Are maintenance and continuous therapies indicated for every patient with multiple myeloma?. <b>2016</b> , 9, 743-51		11
161	Connect MM <sup>2</sup> - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2228-31	1.9	18
160	Oral ixazomib maintenance therapy in multiple myeloma. <b>2016</b> , 16, 21-32		5
159	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. <b>2016</b> , 108,		37
158	Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <b>2016</b> , 11, 127-36		10
157	The safety of pomalidomide for the treatment of multiple myeloma. <b>2016</b> , 15, 535-47		5
156	The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation. <b>2016</b> , 135, 146-55		7
155	Clonal plasma cells keep strange company. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 744-5	1.9	
154	New pharmacotherapy options for multiple myeloma. <b>2016</b> , 17, 181-92		11
153	Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group. <b>2016</b> , 40, 90-9		2
152	Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 888-907	4.5	30
151	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <b>2017</b> , 129, 1308-1319		26
150	A chemical probe toolbox for dissecting the cancer epigenome. <b>2017</b> , 17, 160-183		54
149	Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. <b>2017</b> , 77, 505-520		84
148	Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. <b>2017</b> , 137, 123-131		3
147	Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. <b>2017</b> , 113, 195-212		28
146	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <b>2017</b> , 389, 519-527		496

145	Therapy-related myelodysplastic syndromes, or are they?. <b>2017</b> , 31, 119-128		14
144	New Treatment Methods in Multiple Myeloma. <b>2017</b> , 2, 144-149		0
143	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <b>2017</b> , 4, e431-e442		93
142	Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 479-488	3.8	5
141	The potential for chemotherapy-free strategies in mantle cell lymphoma. <b>2017</b> , 130, 1881-1888		8
140	Other Cancers in CLL, a Common Problem. <b>2017</b> , 17, S38-S40		
139	Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis. <b>2017</b> , 37,		19
138	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <b>2017</b> , 18, 1975-1985		8
137	Targeted therapy and maintenance in myeloma. <b>2017</b> , 122, 163-178		
136	Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma. <b>2017</b> , 33, 279-291		4
135	B-lymphoblastic leukemia/lymphoma arising in treated plasma cell myeloma: A rare second malignancy. <b>2017</b> , 10, 60-63		
134	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <b>2017</b> , 28, 228-245		66
133	Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 773-780	1.9	17
132	Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 560-568	1.9	7
131	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <b>2017</b> , 23, 269-277		15
130	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. <b>2017</b> , 23, 367-378		28
129	Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. <b>2017</b> ,		7
128	Strategie optymalizacji terapii lenalidomidem u chorych na szpiczaka plazmocytoowego. <b>2017</b> , 48, 282-290		

127	Autologous Hematopoietic Cell Transplants for Plasma Cell Myeloma: One, Two, or None?. 445-457		
126	Maintenance Therapy in Plasma Cell Myeloma after Autologous Transplant. 458-467		
125	The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. <b>2017</b> , 1, 2392-2398		14
124	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3279-3289	2.2	361
123	Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-In Most. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3269-3271	2.2	3
122	A systematic classification of death causes in multiple myeloma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 30	7	17
121	Multiple Myeloma. <b>2018</b> , 463-483		
120	Treatment of Transplant Eligible Patients with Multiple Myeloma. <b>2018</b> , 29-60		1
119	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. <b>2018</b> , 24, 930-936		9
118	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2305-2317	1.9	9
117	Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. <b>2018</b> , 6, 155-161		9
116	Co-existence of myeloid neoplasm and monoclonal gammopathy; case series and review of literature. <b>2018</b> , 11, 183-186		
115	Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. <b>2018</b> , 7, 499-507		20
114	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <b>2018</b> , 32, 1542-1560		40
113	Personalized Therapy for Multiple Myeloma. <b>2018</b> ,		1
112	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <b>2018</b> , 32, 712-718		20
111	Treatment of Patients in First or Second Relapse. <b>2018</b> , 77-102		
110	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <b>2018</b> , 131, 301-310		151



109 Post-Transplantation Management Strategies. **2018,**

108 Radiation induced secondary malignancies: a review article. **2018,** 36, 85-94

96

107 An Unprecedented Case of p190 Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature. **2018,** 2018, 7863943

6

106 Increasing therapy-related myeloid neoplasms in multiple myeloma. **2019,** 49, e13050

8

105 Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. **2018,** 5, e479-e492

22

104 Ixazomib: a novel drug for multiple myeloma. **2018,** 11, 761-771

13

103 IMiD compounds affect CD34 cell fate and maturation via CRBN-induced IKZF1 degradation. **2018,** 2, 492-504

9

102 Myelodysplastic Syndromes. **2018,** 944-969.e13

0

101 Second primary malignancy after multiple myeloma-population trends and cause-specific mortality. *British Journal of Haematology*, **2018,** 182, 513-520

4.5 14

100 Update on the role of lenalidomide in patients with multiple myeloma. **2018,** 9, 175-190

25

99 Nutzen bestigt: Lenalidomid nach autologer Stammzelltransplantation. **2018,** 21, 13-14

98 Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. **2018,** 4, 1389-1397

48

97 Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. **2019,** 33, 63-73

26

96 Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. *Cancers*, **2019,** 11,

6.6 4

95 Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?. **2019,** 33, 588-596

4

94 Extramedullary disease in multiple myeloma - controversies and future directions. **2019,** 36, 32-39

35

93 Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. **2019,** 32, 54-64

10

92 Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. *Journal of Clinical Oncology*, **2019,** 37, 589-597

2.2 119

91	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1228-1263	2.2	104
90	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <b>2019</b> , 104, 1440-1450		39
89	The pharmacologic management of multiple myeloma in older adults. <b>2019</b> , 20, 887-902		6
88	Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. <b>2019</b> , 98, e14011		7
87	Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. <b>2019</b> , 125, 550-558		4
86	Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 511-514	1.9	7
85	Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation. <b>2019</b> , 109, 98-106		6
84	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , <b>2020</b> , 99, 309-319	3	4
83	Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma. <i>Cancers</i> , <b>2019</b> , 12,	6.6	0
82	How I manage frontline transplant-eligible multiple myeloma in Italy. <b>2020</b> , 12, 8954		
81	High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients. <b>2020</b> , 10, 563666		4
80	Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2351-2356	3	
79	Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan. <b>2020</b> , 10, 14393		1
78	Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. <b>2020</b> , 126, 3322-3329		2
77	Cytogenetic abnormalities in patients with newly diagnosed multiple myeloma as a secondary primary malignancy: a retrospective study. <b>2020</b> , 25, 176-180		1
76	Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide. <b>2020</b> , 15, 619-633		7
75	The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 692-703	4.5	10
74	Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <b>2021</b> , 106, 1957-1967		6

73	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <b>2020</b> , 34, 1853-1865		26
72	Follow-up issues in survivors of hematologic malignancies - Current stance and future perspectives. <b>2020</b> , 44, 100674		4
71	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <b>2020</b> , 95, 672-690		11
70	Second malignancies in multiple myeloma; emerging patterns and future directions. <b>2020</b> , 33, 101144		11
69	Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients. <b>2020</b> , 12, 431-441		3
68	Maintenance Strategies After Hematopoietic Cell Transplantation. <b>2020</b> , 40, 727-740		0
67	The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1709-1725	3	4
66	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 853-868	4.5	5
65	Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis. <b>2021</b> , 12, 256-261		1
64	Leveraging minimal residual disease to reassess autologous hematopoietic cell transplantation in multiple myeloma. <b>2021</b> , 4, e97		
63	Second primary malignancies in multiple myeloma: A review. <b>2021</b> , 46, 100757		9
62	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 5	7	1
61	Old and new generation immunomodulatory drugs in multiple myeloma. <b>2020</b> , 62, 207-219		2
60	Old and new generation proteasome inhibitors in multiple myeloma. <b>2020</b> , 62, 193-206		1
59	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. <b>2021</b> , 96, E157-E162		2
58	Post-Transplant Maintenance Treatment Options in Multiple Myeloma. <b>2021</b> , 9, 69-88		0
57	Late effects post-autologous hematopoietic stem cell transplantation. <b>2021</b> , 47-57		
56	Second malignancies. <b>2021</b> , 101-111		0

55	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 63	7	0
54	Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. <b>2021</b> , 14, 365-376		
53	What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms. <b>2021</b> , 138, 749-757		2
52	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. <b>2021</b> , 137, 2267-2271		3
51	Future Directions in Maintenance Therapy in Multiple Myeloma. <b>2021</b> , 10,		3
50	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 580-586	4.5	1
49	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 275-282	3.8	3
48	Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China. <b>2021</b> , 11, 665217		0
47	Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. <b>2021</b> , 20, 1137-1145		1
46	Dominance of an mutant clone over a mutant clone: from essential thrombocytemia to VEXAS. <b>2021</b> , 106, 3245-3248		3
45	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <b>2021</b> , 398, 314-324		118
44	Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
43	The role of autologous stem-cell transplantation in multiple myeloma in 2021. <b>2021</b> , 33, 642-647		2
42	Secondary primary malignancies in patients with multiple myeloma: A single institution experience. <b>2021</b> , 39, 674-679		0
41	Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation-A Blood or Marrow Transplant Survivor Study Report. <b>2021</b> , 27, 840.e1-840.e7		0
40	Second Primary Malignancies. <b>2021</b> , 701-710		
39	Plasma Cell Neoplasms. <b>2021</b> , 361-375		
38	Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. <b>2018</b> , 32, 383-390		105

37	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <b>2020</b> , 135, 2375-2387		11
36	Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. <b>2014</b> , 10, 70-79		26
35	Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. <b>2016</b> , 31, 809-19		6
34	Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1398-435	7.3	51
33	NCCN Guidelines Insights: Survivorship, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1016-1023	7.3	31
32	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1685-1717	7.3	43
31	AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: State-of-the-Art Review. <i>JACC: CardioOncology</i> , <b>2021</b> , 3, 467-487	3.8	6
30	Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	1
29	Secondary Malignancies. <b>2015</b> , 375-382		
28	Colorectal Cancer in a Patient With Multiple Myeloma: A Treatment Dilemma. <i>Cureus</i> , <b>2020</b> , 12, e12112	1.2	
27	A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2015</b> , 8, 15025-9	1.4	0
26	[Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2017</b> , 38, 487-493	0.4	
25	[A retrospective clinical analysis of malignant tumor associated with or secondary multiple myeloma]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2018</b> , 39, 1040-1042	0.4	
24	First reported case of secondary mixed phenotype acute leukemia after multiple myeloma. <i>American Journal of Blood Research</i> , <b>2021</b> , 11, 123-131	1.6	3
23	Genome Instability in Multiple Myeloma: Facts and Factors. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
22	Multiples Myelom. <b>2016</b> , 1-17		
21	Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients' Needs. <i>Hemato</i> , <b>2022</b> , 3, 38-46	0.2	
20	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Therapy-Related Hematologic Malignancies Developing After Multiple Myeloma.. <i>European Journal of Haematology</i> , <b>2022</b> ,	3.8	

19	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma.. <i>Seminars in Oncology</i> , <b>2022</b> ,	5.5	1
18	Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 41	7	0
17	Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.. <i>Annals of Hematology</i> , <b>2022</b> , 101, 1031	3	1
16	Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report.. <i>Leukemia Research Reports</i> , <b>2022</b> , 17, 100315	0.6	0
15	Monocytosis and Multiple Myeloma: treatment-related acute leukaemia?. <i>Surgical and Experimental Pathology</i> , <b>2022</b> , 5,	1.6	0
14	Data_Sheet_1.PDF. <b>2020</b> ,		
13	Ciltacabtagene Autoleucel, an AntiB-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> ,	2.2	8
12	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. <i>Leukemia and Lymphoma</i> , 1-10	1.9	1
11	Therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma □ diagnostic and therapeutic dilemma. <i>Acta Oncologica</i> , 1-6	3.2	0
10	Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma. <i>BMJ Case Reports</i> , <b>2022</b> , 15, e249637	0.9	0
9	Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016.		0
8	Response-adapted approach in newly diagnosed myeloma: when less is at least equal. <b>2022</b> , 63, 2021-2022		0
7	Lenalidomide and risk of second primary malignancy□ disease context key?. <b>2022</b> ,		0
6	Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018. <b>2022</b> , 14, 4919		0
5	Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. <b>2022</b> ,		1
4	Survival and response deepening after autologous transplantation in patients with multiple myeloma in Chile. <b>2022</b> , 27, 1223-1229		0
3	Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance. <b>2023</b> , 13, 412		0
2	Clinicopathologic features of therapy-related myeloid neoplasms in myeloma patients in the era of novel therapies. <b>2023</b> , 100166		0

- 1 Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.

o